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Patients with Turner syndrome (TS) require close medical follow-up and management for cardiac ab-
normalities, growth and reproductive issues. This review summarizes current controversies in this
condition, including: 1) the optimal genetic testing for Turner syndrome patients, particularly with
respect to identiﬁcation of Y chromosome material that may increase the patient’s risk of gonado-
blastoma and dysgerminoma, 2) which patients should be referred for bilateral gonadectomy and the
recommended timing of such referral, 3) options for assisted reproduction in these patients and asso-
ciated risks, 4) the increased risk of mortality associated with pregnancy in this population, and 5) how
best to assess and monitor cardiovascular risks.
 2014 The Authors. Published by Elsevier Inc. All rights reserved.Introduction
Turner syndrome is a heterogenous genetic disorder caused by
loss of the short arm of the X chromosome, and it affects approxi-
mately 1 out of 2500 newborn females. Classic Turner syndrome
associated with 45,X karyotype occurs in approximately 45% of
cases and is characterized by short stature, ovarian insufﬁciency,
nuchal folds, low hairline, low set ears, high-arched palate, wide-
spaced nipples (shield chest), left-sided cardiac anomalies, cubi-
tus valgus (wide carrying angle), shortened fourth metacarpal, and
nail abnormalities. Mosaic Turner syndrome accounts for the
remaining 55% of cases and has a highly variable phenotype
depending on the region(s) of missing X chromosome and/or the
proportion and location of affected cells. Due to the variable and
often more subtle phenotypic characteristics caused by mosaic X
chromosome loss, diagnosis of these patients is often delayed or
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patients with low-level mosaicism share similar risks and require
similar monitoring as patients with classic Turner syndrome.
Endocrinologists are charged with evaluation and management
of growth failure, ovarian insufﬁciency and estrogen replacement,
and infertility. In addition, endocrinologists guide families toward
subspecialty management of additional issues, such as cardiac ab-
normalities. For general reviews of these topics, readers are referred
to Refs. [1e3]. This review focuses on the controversial issues of
genetic testing for Y chromosome material as it relates to risk of
gonadoblastoma and need for prophylactic gonadectomy, as well as
assisted reproduction in patients with signiﬁcant peri-partum car-
diovascular risks. Although ﬁrm guidelines have not yet been
established regarding these issues, we aim to provide the reader
with recommendations for their clinical practices.
Genetic testing for Y chromosome material
The presence of Y chromosome material is associated with
increased risk of gonadoblastoma and germ cell tumors in patients
with Turner syndrome (reviewed in Ref. [4]). Unfortunately, cryptic
mosaicism for Y chromosome material may not be detected by
standard cytogenetic techniques, which typically analyze 20e30
peripheral lymphocytes in metaphase [5]. Therefore, speciﬁc mo-
lecular testing for Y chromosome material must be performed in
patients for whom the diagnosis is not clear (i.e. patients with a
45,X karyotype, see Figure 1). The preferredmethod for such testing
is ﬂuorescent in situ hybridization (FISH) for the Y-centromerets reserved.
Figure 1. Recommended genetic testing for Turner syndrome.
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gonadoblastoma risk [6e8]. Importantly, FISH for the SRY gene is
not speciﬁc to this region, and polymerase chain reaction (PCR) is
susceptible to contamination [9].
All patients with 45,X karyotype should be evaluated speciﬁcally
for Y chromosome material. Patients with mosaic Turner syndrome
identiﬁed cytogenetically whose second cell line contains an
additional chromosome that is either an X or derived from an X do
not require further molecular testing because, by deﬁnition, the
origin of their mosaicism has been determined. True sex chromo-
some monosomy (45,X or 45,Y) is incompatible with life; the
presence of at least a partial second sex chromosome in a mosaic
fashion is necessary [10]. The mosaicism is hypothesized to arise
from the presence of a second (“rescue”) embryonic cell line that
comprises only a small percentage of adult cells and consequently is
not detected by conventional cytogenetic analysis. Thus, patients
with 45,X karyotype may have a second cell line containing Y
chromosome material that increases their risk of gonadoblastoma.
There is wide variability in the reported prevalence of Y chro-
mosome material, gonadoblastoma, and dysgerminomas in Turner
syndrome, likely due to differences in clinical practice regarding
methods of genetic testing, recommendation for gonadectomy, and
pathology analysis. A review of three studies in 2005 revealed that
Y chromosomematerial is present in 8e12% of patients with Turner
syndrome. Approximately 27% of this subset of patients have
histologically-conﬁrmed gonadoblastoma and 4% of these patients
have evidence of malignant transformation (14% of patients with
gonadoblastoma) [11]. The etiology of gonadoblastoma and mech-
anism of transformation to germ cell tumors are unclear [12].
Although a speciﬁc genemutation has not been associatedwith this
neoplasm, several groups have provided evidence that TSPY is the
gonadoblastoma-susceptibility gene located within the centro-
meric region of the Y chromosome (reviewed in Ref. [8]). Interest-
ingly, there is some evidence that gonadoblastoma is a congenital,
rather than progressive, disorder due to fetal germ cell dysgenesis
[13]. In fact, gonadoblastoma has been identiﬁed in infants with
Turner syndrome. There is a theoretical concern that growth hor-
mone therapy may increase the risk of gonadoblastoma and/or
malignant transformation, but no evidence supporting this has
been presented to date.
Because of the uncertain pathophysiology and natural history of
gonadoblastoma, it is recommended that all patients with either
45,X/46,XY mosaic karyotype or 45,X with positive DYZ3 FISH
analysis be referred for bilateral gonadectomy [14]. However, it is
important to keep in mind that identiﬁcation of Y chromosomematerial in peripheral blood samples does not necessarily reﬂect
presence of Y chromosomematerial in gonadal tissue [15], which is
most likely directly related to gonadoblastoma formation. An age
threshold for gonadectomy has not been established in this patient
population, particularly because evidence is lacking that screening
with ultrasound, MRI, or serum tumor markers are sufﬁciently
sensitive to identify gonadoblastoma prior to transformation to
germ cell tumor [14]. Unfortunately, gonadal biopsy is likely also
insufﬁciently sensitive to identify all cases of gonadal Y chromo-
some material, gonadoblastoma, and/or germ cell tumor, as only a
small tissue region is analyzed.
It is unclear if patients with previously established 45,X non-
mosaic Turner syndrome who had never been assessed for Y ma-
terial in the past should now undergo retrospective targeted search,
and if there should be an age cutoff for this. In the absence of evi-
dence, it is reasonable to retroactively perform FISH for DYZ3 locus
in patients with previously-identiﬁed 45,X karyotypes. Those pa-
tients with positive DYZ3 FISH should be referred to Urology and
Reproductive Endocrinology for discussion of the risks and beneﬁts
of gonadectomy. Further studies are needed to address these
important questions.
Because patients with classic and 45,X/46,XY mosaic Turner
syndrome have low fertility potential, gonadectomy may be
considered of little consequence. However, many patients and their
families may have difﬁculty consenting to a procedure that reduces
or eliminates that potential, particularly when the risks associated
with delaying or refusing gonadectomy are somewhat unclear.
Patients with complete androgen insensitivity syndrome (CAIS)
face similar considerations because they are also at increased risk
for gonadoblastoma and germ cell tumors, although they are unable
to carry a pregnancy [16]. Bilateral gonadectomy is recommended
in all patients with CAIS but is often delayed until after puberty
because most patients with CAIS develop secondary female sex
characteristics at the appropriate pubertal age due to conversion of
elevated testosterone levels to estrogen. The decision to delay go-
nadectomy also may be more appropriate in the CAIS population
because of the lower rate of gonadal dysgenesis compared to pa-
tients with Turner syndrome, although there certainly are pro-
ponents of early gonadectomy in all cases given the malignant
potential of intra-abdominal dysgenic gonadal tissue.
Reproductive potential
Between 15% and 40% of adolescents with Turner syndrome
undergo spontaneous puberty, although only 2e10% have
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patients with mosaic X chromosome disomy tends to be higher
[18]. Therefore, current guidelines recommend waiting until 12e13
years of age before initiating estrogen replacement therapy in the
absence of appropriate pubertal progression [1,19]. Elevated follicle
stimulating hormone (FSH) and anti-Mullerian hormone (AMH)
levels also indicate ovarian insufﬁciency/failure and may represent
need for exogenous estrogen. Only 2e5% of patients with Turner
syndrome become pregnant spontaneously [17,20]. Thus, many
patients seek assisted reproductive technology (ART) in their young
adult and adult years.
Notably, in 2012, the American Society of ReproductiveMedicine
identiﬁed Turner syndrome as a relative contraindication to preg-
nancy, and an absolute contraindication in those with documented
cardiac anomalies [48]. This is due to high risk of cardiac-associated
death, even in those with normal cardiac evaluations. Thus, the
topics of preserving or assisting reproductive capabilities in pa-
tients with Turner syndrome are controversial, and safer alterna-
tives such as surrogacy or adoption should be considered.
For those who wish to pursue assisted reproduction, one must
proceed cautiously. The most commonly utilized method is via
vitro fertilization (IVF) of the patient’s harvested oocytes and
embryo transfer to the patient’s uterus. The oocytes may be either
fresh or derived from previously cryo-preserved ovarian tissue.
Importantly, ovarian follicle cryopreservation may be a consider-
ation for patients undergoing gonadectomy due to presence of Y
centromeric material, particularly because there may be more
viable follicles at younger ages (reviewed in Refs. [17,21,22]).
Although this procedure has resulted in successful pregnancies in
females without Turner syndrome (i.e. cancer survivors whose
ovarian tissue was cryopreserved prior to gonadotoxic chemo-
therapy), it has not yet been reported to lead to successful preg-
nancy in the Turner syndrome population. Overall, the success
rate of IVF producing a live birth in patients with Turner syndrome
is approximately 50%, although at least half of these pregnancies
have signiﬁcant complications including pregnancy-induced hy-
pertension, preterm delivery, low birth weight, and need for
Caesarean section [20,23,24]. Furthermore, in addition to the
typical risks associated with IVF, patients with Turner syndrome
have signiﬁcantly increased mortality during and after pregnancy
related to cardiovascular abnormalities.
Increased risk of cardiovascular death
Patients with Turner syndrome are at increased risk of having
congenital left-sided cardiac anomalies and/or developing cardio-
vascular abnormalities during their lifetime, associated with
signiﬁcantly increased morbidity and mortality (reviewed in
Ref. [26]). Kim et al. [27] found that 16% of patients with Turner
syndrome have aortic coarctation, 39% have bicuspid aortic valve,
and 16% had partial anomalous pulmonary venous return (PAPVR).
Olivieri et al. [28] similarly identiﬁed that 36% of patients with
Turner syndrome have some type of aortic valve anomaly (23%
bicuspid, 12% partially fused, 1% unicuspid), and that these anom-
alies are associated with increased diameter of the ascending aorta.
These left-sided cardiac anomalies, in addition to hypertension,
increase the risk of aortic dissection and death. Aortic dissection is
six times more likely to occur in patients with Turner syndrome
compared to the general female population [29] and at a signiﬁ-
cantly younger age (average 30 years versus 68 years in the general
population). Importantly, aortic dissection occurs in patients with
Turner syndrome with aortic root and ascending aorta diameters
that are well below the standard threshold of concern for the
general population [30]. Thus, it is important to identify early and
small increases in aortic root and ascending aorta diameter.Cardiac MRI has been proposed to have higher sensitivity than
echocardiography for identiﬁcation of cardiac abnormalities in pa-
tients with Turner syndrome (reviewed in Ref. [31]). This seems to
be related both to technological differences, as well as increased
thoracic antero-posterior diameter and increased lymphatic tissue
in patients with Turner syndrome. Importantly, aorta measure-
ments should take into account the smaller size of patients with
Turner syndrome; the most widely accepted method is normali-
zation to patient body surface area (BSA), which is termed aortic
size index (ASI ¼ diameter/BSA). However, normal ASI values for
different ages, as well as thresholds of concern, in patients with
Turner syndrome are not ﬁrmly established.
Notably, some patients with Turner syndrome without any ev-
idence of cardiac anomaly or cardiovascular disease develop aortic
dissection, and the associatedmortality rate is quite high (63%) [30].
There is also evidence that aortic dilation is not necessarily pro-
gressive in this population [32e34], in contrast to other patient
populations at increased risk for aortic dilation and dissection such
as Marfan, Ehlers-Danlos, and Loeys-Dietz syndromes [35]. These
other syndromes are all classiﬁed as connective tissue disorders, of
which Turner syndrome shares some characteristics. In fact, pa-
tients with Turner syndrome exhibit decreased aortic distensibility,
particularly in the setting of aortic dilation [36], as well as increased
carotid intima-media thickness and pulse wave velocity [37,38].
Furthermore, at least 50% of patients with Turner syndrome
develop hypertension, half of these by adolescence [39]. It is
important to note that growth hormone and estrogen replacement
therapies have not been associated with signiﬁcant changes in
aortic diameter when normalized to body size [40,41]. Although it
is clear that all patients with Turner syndrome require careful
assessment of cardiovascular risk, it has been difﬁcult to establish
deﬁnitive guidelines for cardiac monitoring due to the unclear
pathophysiology and prognosis associated with identiﬁable
anomalies.
Pregnancy seems to be an independent risk factor for aortic
dissection in Turner syndrome, as women with a prior pregnancy
were over-represented (15%) in a registry of patients who suf-
fered from aortic dissection [30]. Partly driven by this evidence,
abnormalities on cardiac imaging is also considered a contrain-
dication to pregnancy. Overall, pregnancy is associated with a 2%
mortality risk in patients with Turner syndrome, primarily due
to aortic dissection [24,42], whereas the risk for maternal death
in the general population is 1/10,000 [48]. The precise mecha-
nisms responsible for this increased risk are not clear, although it
is theorized to be related to the normal increases in stroke vol-
ume and cardiac output during pregnancy [43e45], which place
stress on the heart and vasculature. This also may explain why
multiple gestation pregnancies, which result in further increases
in cardiac output [46], are associated with even higher cardio-
vascular mortality risk [25]. It is important to remember that the
cardiovascular changes that occur during pregnancy are chronic
and increase mortality risk for the remainder of the patient’s
lifetime.
Currently, cardiovascular screening recommendations for pa-
tients with Turner syndrome include EKG and imaging at the time
of diagnosis (echocardiography in young patients who would
otherwise require sedation for MRI, and cardiac MRI in older
children and adults), follow-up imaging every 5e10 years if
normal, and annual blood pressure measurements [1]. Patients
should be referred to and followed by a cardiologist. Prior to
pregnancy, women should be screened with blood pressure
measurement and cardiac imaging, and they should also be
counseled regarding the crucial risks of pregnancy. Blood pressure
and cardiac imaging assessments should be repeated frequently
throughout pregnancy and the early post-partum period [47]. In
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ASI of >2 cm/m2, is considered an absolute contraindication to
pregnancy in patients with Turner syndrome, due to risk of aortic
dissection and death [48].Discussion
Here we reviewed several current controversial topics in the
comprehensive care of patients with Turner syndrome, and we
identify several areas that need further study. As more has been
learned regarding the etiology of Turner syndrome, it has become
clear that nearly all patients have a mosaic cell line with a second
sex chromosome, which results in a broad spectrum of clinical
phenotypes and associated risks. An important implication of
having Y chromosome material is the risk of malignant trans-
formation of gonadoblastoma, necessitating molecular genetic
testing. Speciﬁcally for patients in whom a second X chromosome
or a marker chromosome was not detected by karyotype, FISH for
the DYZ3 locus should be performed followed by immediate bilat-
eral gonadectomy if such genetic testing is positive. However,
further studies are needed to evaluate the pathophysiology and
prevalence of gonadoblastoma and germ cell tumors in these pa-
tients in order to provide stronger evidence for optimal genetic
testing and for recommendations regarding timing of gonadectomy.
Furthermore, in light of recognized increase in mortality and
morbidity, it is imperative to recognize and counsel patients
regarding the signiﬁcant cardiovascular and mortality risks asso-
ciated with pregnancy. Additional studies to elucidate the under-
lying pathophysiology and prognosis of cardiovascular
abnormalities in these patients are critical so that evidence-based
recommendations can be made regarding method(s) and timing
of cardiovascular evaluation.
In the absence of strong evidence-based guidelines, current
practice with respect to these issues relies on the principle of “ﬁrst
do no harm.” As a result, some patients may be undergoing un-
necessary (and expensive) testing, whereas other patients may not
be receiving sufﬁcient testing or intervention and likely are
suffering from increased morbidity and mortality. It is important to
educate patients and their families regarding these controversies
and discuss them openly in order to provide a context for the
recommendations.Acknowledgments
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